Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Sarepta Therapeutics (NASDAQ:SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

Roche, the company to which the treatment is ... HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range. Analyst Mitchell S.

Sarepta and Roche plan to submit the DMC's findings to EU regulators "within a week" for review. Related. Sarepta reports one death after patient received DMD gene therapy Elevidys.

Roche (RHHBY) sent a letter dated March 31 to the World Duchenne Organization stating the European Medicines Agency requested a temporary clinical hold on three studies involving Sarepta’s (SRPT ...

Serepta and global partner Roche have discontinued the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) in non-ambulatory ...

Sarepta and Roche paused multiple Elevidys trials in the EU at the EMA’s request. HC Wainwright upgraded Sarepta to Neutral but sees Elevidys sales falling by Q2 2025. Last Chance: See the ...

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.